Is Pfizer’s loss is Ranbaxy’s gain: The Billion Dollar Lipitor question

/, Public Health/Is Pfizer’s loss is Ranbaxy’s gain: The Billion Dollar Lipitor question

Is Pfizer’s loss is Ranbaxy’s gain: The Billion Dollar Lipitor question

Way back when I was in B school the burning question in the Indian pharmaceutical industry was the expiring patents of the global pharmaceutical companies. The top among the list was Lipitor the anti hypertensive drug that was fuelling most of Pfizer’s revenues.

Lipitor was the first drug to exceed $10 billion a year in sales, and accounted for almost one-quarter of Pfizer’s revenue in the last decade. But all that has changed once Lipitor comes off the paptent list on November 30th. This allows companies like Ranbaxy to launch the gheneric version of Lipitor with a

By |2016-08-09T07:24:19+00:00November 30th, 2011|Healthcare Delivery, Public Health|0 Comments

About the Author:

Dr. Vikram Venkateswaran, Post Graduate Diploma in Clinical Research, B.D.S in Dental Surgery, & MBA in Strategy. An author and speaker at business forums. A business leader and digital evangelist. He is the founder of Healthcare India, a social movement for better health. Visit Dr. Vikram Venkateswaran's profile, for further details.

Leave A Comment

This site uses Akismet to reduce spam. Learn how your comment data is processed.